Propentofylline decreases tumor growth in a rodent model of glioblastoma multiforme by a direct mechanism on microglia

Neuro-Oncology

Volumn 14, Issue 2, 2012, Pages 119-131

  Jacobs, Valerie L ^a,b   Landry, Russell P ^a   Liu, Yingna ^a   Romero Sandoval, Edgar Alfonso ^b   De Leo, Joyce A ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Glioma; macrophages; microglia; migration; MMP 9

Indexed keywords

CD11B ANTIGEN; GELATINASE B; PROPENTOFYLLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER SIZE; CANCER SURVIVAL; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROGLIA; NONHUMAN; PROTEIN EXPRESSION; RAT; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; GLIOBLASTOMA; HUMANS; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 9; MICROGLIA; NEOPLASM INVASIVENESS; RATS; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; XANTHINES;

EID: 84859518369     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor194     Document Type: Article

References (52)

1. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479-489. (Pubitemid 40781150)
2. Meyer MA. Malignant gliomas in adults. N Engl J Med. 2008;359(17):1850; author reply 1850.
3. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492-507.
4. Shapiro WR. Therapy of adult malignant brain tumors: what have the clinical trials taught us? Semin Oncol. 1986;13(1):38-45. (Pubitemid 16116039)
5. Tuettenberg J, Grobholz R, Seiz M, et al. Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy. J Cancer Res Clin Oncol. 2009;135(9):1239-1244.
6. Benesch M, Weber-Mzell D, Gerber NU, et al. Ependymoma of the spinal cord in children and adolescents: a retrospective series from the HIT database. J Neurosurg Pediatr. 2010;6(2):137-144.
7. Gabelloni P, Da Pozzo E, Bendinelli S, et al. Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma. Neuroscience. 2010;168(2):514-522.
8. Yang I, Han SJ, Kaur G, Crane C, Parsa AT. The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosci. 2010;17(1):6-10.
9. Roggendorf W, Strupp S, Paulus W. Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol. 1996;92(3):288-293. (Pubitemid 26278960)
10. Bettinger I, Thanos S, Paulus W. Microglia promote glioma migration. Acta Neuropathol. 2002;103(4):351-355. (Pubitemid 36097029)
11. Markovic DS, Glass R, Synowitz M, Rooijen N, Kettenmann H. Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2. J Neuropathol Exp Neurol. 2005;64(9): 754-762. (Pubitemid 41285807)
12. Wagner S, Czub S, Greif M, et al. Microglial/macrophage expression of interleukin 10 in human glioblastomas. Int J Cancer. 1999;82(1):12-16. (Pubitemid 29266099)
13. Huettner C, Czub S, Kerkau S, RoggendorfW, Tonn JC. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res. 1997;17(5A):3217-3224. (Pubitemid 27522273)
14. Esteve PO, Chicoine E, Robledo O, et al. Protein kinase C-zeta regulates transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-alpha in glioma cells via NF-kappa B. J Biol Chem. 2002;277(38):35150-35155.
15. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009;27(31):5287-5297.
16. Kim SY, Lee EJ, Woo MS, et al. Inhibition of matrix metalloproteinase-9 gene expression by an isoflavone metabolite, irisolidone in U87MG human astroglioma cells. Biochem Biophys Res Commun. 2008;366(2):493-499.
17. Rao JS, Yamamoto M, Mohaman S, et al. Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis. 1996;14(1):12-18. (Pubitemid 26009751)
18. Groves MD, Puduvalli VK, Hess KR, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol. 2002;20(5): 1383-1388. (Pubitemid 34177446)
19. Levin VA, Phuphanich S, Yung WK, et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol. 2006;78(3):295-302. (Pubitemid 44018824)
20. Fingleton B. MMPs as therapeutic targets-still a viable option? Semin Cell Dev Biol. 2008;19(1):61-68. (Pubitemid 350235985)
21. Sweitzer S,De Leo J. Propentofylline: glialmodulation, neuroprotection, and alleviation of chronic pain. Handb Exp Pharmacol. 2011;(200):235-250.
22. Salimi S, Fotouhi A, Ghoreishi A, et al. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(3):726-732. (Pubitemid 351312372)
23. Kittner B. Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group. Alzheimer Dis Assoc Disord. 1999;13(Suppl 3):S166-S171.
24. Nagata K, Ogawa T, Omosu M, Fujimoto K, Hayashi S. In vitro and in vivo inhibitory effects of propentofylline on cyclic AMP phosphodiesterase activity. Arzneimittelforschung. 1985;35(7):1034-1036. (Pubitemid 15033418)
25. Fredholm BB, Lindstrom K. The xanthine derivative 1-(5′-oxohexyl)- 3-methyl-7-propyl xanthine (HWA 285) enhances the actions of adenosine. Acta Pharmacol Toxicol (Copenh). 1986;58(3):187-192. (Pubitemid 16080510)
26. Si Q, Nakamura Y, Ogata T, Kataoka K, Schubert P. Differential regulation of microglial activation by propentofylline via cAMP signaling. Brain Res. 1998;812(1-2):97-104. (Pubitemid 29005336)
27. Si QS, Nakamura Y, Schubert P, Rudolphi K, Kataoka K. Adenosine and propentofylline inhibit the proliferation of cultured microglial cells. Exp Neurol. 1996;137(2):345-349. (Pubitemid 26081893)
28. Kruse CA, Molleston MC, Parks EP, Schiltz PM, Kleinschmidt-DeMasters BK, Hickey WF. A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: a comparison to 9L gliosarcoma. J Neurooncol. 1994;22(3):191-200.
29. Candolfi M, Curtin JF, Nichols WS, et al. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol. 2007;85(2):133-148. (Pubitemid 47629395)
30. Kielian T, van Rooijen N, Hickey WF. MCP-1 expression in CNS-1 astrocytoma cells: implications for macrophage infiltration into tumors in vivo. J Neurooncol. 2002;56(1):1-12. (Pubitemid 34256612)
31. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24(3):148-154. (Pubitemid 19163397)
32. Samkoe KS, Chen A, Rizvi I, et al. Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft models. Int J Radiat Oncol Biol Phys. 2010;76(1):251-259.
33. Nutile-McMenemy N, Elfenbein A, Deleo JA. Minocycline decreases in vitro microglial motility, beta1-integrin, and Kv1.3 channel expression. J Neurochem. 2007;103(5):2035-2046. (Pubitemid 350126620)
34. Horvath RJ, Nutile-McMenemy N, Alkaitis MS, Deleo JA. Differential migration, LPS-induced cytokine, chemokine, and NO expression in immortalized BV-2 and HAPI cell lines and primary microglial cultures. J Neurochem. 2008;107(2):557-569.
35. Troeberg L, Nagase H. Zymography of metalloproteinases. Curr Protoc Protein Sci. 2004;15:1-15.
36. Hamachi Y, Nakashima MN, Nakashima K. High-performance liquid chromatography with peroxyoxalate chemiluminescence determination of propentofylline concentrations in rat brain microdialysate. J Chromatogr B Biomed Sci Appl. 1999;724(1):189-194. (Pubitemid 29146035)
37. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer. 2003;3(7):489-501. (Pubitemid 37328837)
38. Regina A, Demeule M, Berube A, Moumdjian R, Berthelet F, Beliveau R. Differences in multidrug resistance phenotype and matrix metalloproteinases activity between endothelial cells from normal brain and glioma. J Neurochem. 2003;84(2):316-324. (Pubitemid 36182273)
39. Kong LY, Wu AS, Doucette T, et al. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res. 2010;16(23):5722-5733.
40. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21(21):2683-2710. (Pubitemid 350070717)
41. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006;8(3):261-279. (Pubitemid 46542651)
42. Zhang L, Alizadeh D, Van Handel M, Kortylewski M, Yu H, Badie B. Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia. 2009;57(13):1458-1467.
43. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest. 2010;120(3):694-705.
44. Wu A, Wei J, Kong LY, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010;12(11): 1113-1125.
45. Ginhoux F, Greter M, Leboeuf M, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330(6005):841-845.
46. Durafourt BA, Lambert C, Johnson TA, Blain M, Bar-Or A, Antel JP. Differential responses of human microglia and blood-derived myeloid cells to FTY720. J Neuroimmunol. 2010;230(1-2):10-16.
47. Lambert C, Ase AR, Seguela P, Antel JP. Distinct migratory and cytokine responses of human microglia and macrophages to ATP. Brain Behav Immun. 2010;24(8):1241-1248.
48. Schmid CD, Melchior B, Masek K, et al. Differential gene expression in LPS/IFNgamma activated microglia and macrophages: in vitro versus in vivo. J Neurochem. 2009;109(Suppl 1):117-125.
49. Kamada H, Murakami H, Satone A, et al. [Up-regulation of NGF, trkA, Fas, down-regulation of bcl-2, and induction of apoptosis by propentofylline in human glioma cell lines]. No To Shinkei. 1996;48(11):1022-1028.
50. Satone A, Ukita H, Murakami H, et al. [Neural protective agents, propentofylline (PPF) could induce apoptotic cell death in the human glioma cells: analysis of Bcl-2 and Bax alpha/Bax beta expressions]. No To Shinkei. 1998;50(4):330-337. (Pubitemid 28233140)
51. Yamaguchi H, Ukita H, Murakami H, et al. [Induction of apoptosis through NGF/p75NTR in human glioma cells treated with propentofylline]. No To Shinkei. 1998;50(5):407-414. (Pubitemid 28259312)
52. Jacobs VL, Valdes PA, Hickey WF, De Leo JA. Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model. ASN Neuro. [Published online ahead of print July 8, 2011].